EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

CRISPR screening redefines therapeutic target identification and drug discovery with precision and scalability

Yao He, Xiao Tu, Yuxin Xue, Yuxuan Chen, Bengui Ye, Xiaojie Li, Dapeng Li, Zhihui Zhong, Qixing Zhong

Journal of Pharmaceutical Analysis · 2026-02 · 16 (2) · 101357

DOI: 10.1016/j.jpha.2025.101357 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Pharmaceutical Analysis, 2026-02. Verfasst von Yao He und 8 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Neurological Disease Modeling and Translational Research, West China Hospital, Sichuan University, Chengdu, 610041, China. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 151 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Sichuan Province Science and Technology Support Program, Natural Science Foundation of Sichuan Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 screening technology is redefining the landscape of drug discovery and therapeutic target identification by providing a precise and scalable platform for functional genomics. The development of extensive single-guide RNA (sgRNA) libraries enables high-throughput screening (HTS) that systematically investigates gene-drug interactions across the genome. This powerful approach has found broad applications in identifying drug targets for various diseases, including cancer, infectious diseases, metabolic disorders, and neurodegenerative conditions, playing a crucial role in elucidating drug mechanisms and facilitating drug screening. Despite challenges like off-target effects, data complexity, and ethical or regulatory concerns, ongoing advancements in CRISPR technology and bioinformatics are steadily overcoming these limitations. Additionally, by integrating with organoid models, artificial intelligence (AI), and big data technologies, CRISPR screening expands the scale, intelligence, and automation of drug discovery. This integration boosts data analysis efficiency and offers robust support for uncovering new therapeutic targets and mechanisms. This review outlines the fundamental principles and applications of CRISPR screening technology, delves into specific case studies and technical challenges, and highlights its expanding role in drug discovery and target identification. It also examines the potential for clinical translation and addresses the associated ethical and regulatory considerations.

Schlagwörter

Stichwörter der Autor:innen

CRISPR-CasDrug discoveryGene editingTargets identification

Autor:innen und Institutionen

  • Laboratory of Neurological Disease Modeling and Translational Research, West China Hospital, Sichuan University, Chengdu, 610041, China.
  • Medical Innovation Center, Sichuan University of Science & Engineering, Zigong, Sichuan, 643002, China.
  • Key Laboratory of Drug Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial T…
  • Medical College of Tibet University, Lasa, 850002, China.
  • Tianfu Jincheng Laboratory, City of Future Medicine, Chengdu, 641400, China.

Förderung

  • National Natural Science Foundation of China
  • Sichuan Province Science and Technology Support Program
  • Natural Science Foundation of Sichuan Province
  • Sichuan University

Zitieren

APA

He, Y., Tu, X., Xue, Y., Chen, Y., Ye, B., Li, X., Li, D., Zhong, Z., & Zhong, Q. (2026). CRISPR screening redefines therapeutic target identification and drug discovery with precision and scalability. Journal of Pharmaceutical Analysis, 16(2), 101357. https://doi.org/10.1016/j.jpha.2025.101357

Vancouver

He Y, Tu X, Xue Y, Chen Y, Ye B, Li X, et al. CRISPR screening redefines therapeutic target identification and drug discovery with precision and scalability. Journal of Pharmaceutical Analysis. 2026;16(2):101357. doi:10.1016/j.jpha.2025.101357

BibTeX
@article{He2026,
  author = {He, Yao and Tu, Xiao and Xue, Yuxin and Chen, Yuxuan and Ye, Bengui and Li, Xiaojie and Li, Dapeng and Zhong, Zhihui and Zhong, Qixing},
  title = {CRISPR screening redefines therapeutic target identification and drug discovery with precision and scalability},
  journal = {Journal of Pharmaceutical Analysis},
  year = {2026},
  volume = {16},
  number = {2},
  pages = {101357},
  doi = {10.1016/j.jpha.2025.101357}
}
Kostenlos starten →